4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: A novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1405-1414

  Narla, Rama Krishna ^a   Liu, Xing Ping ^a   Myers, Dorothea E ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3' BROMO 4' HYDROXYLPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL DEATH; CYTOTOXICITY; DRUG POTENCY; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; RECEPTOR GENE; TARGET CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; MICE; MICE, SCID; QUINAZOLINES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031801528     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pardos, M. D., and Wilson, C. B. Neoplasms of the central nervous system. In: J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Frei III, D. W. Kufe, and R. R. Weichselbaum (eds.) Cancer Medicine, Vol. I, pp. 1471-1514. Baltimore: Williams and Wilkins, 1997.
2. Brandes, A. A., and Fiorentino, M. V. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest., 14: 551-559, 1996.
3. Finlay, J. L. Chemotherapeutic strategies for high grade astrocytoma of childhood. In: R. J. Packer, W. A. Bleyer, and C. Pochedly (eds.), Pediatric Neuro-Oncology, pp. 278-297. Philadelphia: Harwood Academics, 1992.
4. Pardos, M. D., and Russo, C. Chemotherapy of brain tumors. Semin. Surg. Oncol., 14: 88-95, 1998.
5. Nomoto, F., Obase, H., Takai, H., Hirata, T., Teranishi, M., Nakamura, J., and Kubo, K. Studies on cardiotic agents. I. Synthesis of quinazoline derivatives. Chem. Pharm. Bull., 38: 1591-1595, 1990.
6. Thomas, C. L. Catalytic Processes and Proven Catalysts, pp. 1-27. New York: Academic Press, 1970.
7. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Tuel-Ahlgren, L., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinase. Science (Washington DC), 267: 886-891, 1995.
8. Feng, R., Konishi, Y., and Bell, A. W. High accuracy molecular weight determination and variation, characterization of proteins up to 80 KU by ion spray mass spectrometry. J. Am. Soc. Mass Spectrom., 2: 387-401, 1991.
9. Covey, T. R., Bonner, R. S., Shushan, B. I., and Henion, J. D. Determination of protein oligonucleotides and peptides molecular weights by ion spray mass spectometry. Rapid Commun. Mass Spectrom., 2: 249-256, 1988.
10. Friedman, S. H., Dolan, M. E., Pegg, A. E., Marcelli, S., Keir, S., Catino, J. J., Binger, D. D., and Schold, S. C., Jr. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
11. Waurzyniak, B., Shneider, E. A., Tumer, N., Yanishevski, Y., Gunther, R., Chelstrom, L., Wendorf, H., Myers, D. E., Irvin, J. D., Messinger, Y., Ek, O., Zeren, T., Chandan-Langlie, M., Evans, W. E., and Uckun, F. M. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin. Cancer Res., 3: 881-890, 1997.
12. Anderson, P. M., Meyers, D. E., Hasz, D. E., Covalcuic, K., Saltzman, D., Khanna, C., and Uckun, F. M. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. Cancer Res., 55: 1321-1327, 1995.
13. Uckun, F. M., Gaynon, P., Sensel, M., Nachman, J., Trigg, M., Steinherz, P., Hutchinson, R., Bostrom, B., Lange, B., Sather, H., and Reaman, G. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a children's cancer group study. J. Clin. Oncol., 15: 2214-2221, 1997.
14. Bos, M., Mendelsohn, J., Kim, Y., Albanell, J., Fry, D. W., and Baselga, J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res., 3: 2099-2106, 1997.
15. Fry, D. W., Kraker, A., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. L. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
16. Khazaie, K., Schirrmacher, V., and Lichtner, R. B. EGF receptor in neoplasia and metastasis (Review). Cancer Metastasis Rev., 12: 255-274, 1993.
17. Maruno, M., Kovach, J. S., Kelly, P. J., and Yanagihara, T. Transforming growth factor α, epidermal growth factor receptor, and proliferating potential in benign and malignant gliomas. J. Neurosurg., 75: 97-102, 1991.
18. Yamazaki, H., Fukui, Y., Ueyama, Y., Tamaoki, N., Kawamoto, T., Taniguchi, S., and Shibuya, M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erb-B) in human brain tumors. Mol. Cell. Biol., 8: 1816-1820, 1988.
19. Torp, S. H., Helseth, E., Dalen, A., and Unsgaard, G. Epidermal growth factor receptor expression in human glioma. Cancer Immunol. Immunother., 33: 61-64, 1991.
20. Hoi Sang, U., Espiritu, O. D., Kelley, P. Y., Klauber, M. R., and Hatton, J. D. The role of epidermal growth factor receptor in human gliomas: I. The control of cell growth. J. Neurosurg., 82: 841-846, 1995.
21. Mendelsohn, J., and Baselga, J. Antibodies to growth factors and receptors. Biologic Therapy of Cancer: Principles and Practice, pp. 607-623, 1995.
22. Uckun, F. M., Narla, R. K., Jun, X., Zeren, T., Venkatachalam, T., Waddick, K. G., Rostostev, A., and Myers, D. E. Cytotoxic activity of EGF-genistein against breast cancer cells. Clin. Cancer Res., 4: 901-912, 1998.
23. Uckun, F. M., Narla, R. K., Zeren, T., Yanishevski, Y., Meyers, D. E., Waurzyniak, B., Ek, O., Schneider, E., Messinger, Y., Chelstrom, L., Gunther, R., and Evans, W. In vivo toxicity, pharmacokinetics, and anti-cancer activity of genistein linked to recombinant human epidermal growth factor. Clin. Cancer Res., 4: 1125-1134, 1998.